Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : OncoGenex Technologies, Inc
Homme Max 99 ans
OncoGenex Technologies, Inc
MAJ Il y a 5 ans
A study to assess prostate cancer pain with the addition of custirsen
Ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
OncoGenex Technologies, Inc
MAJ Il y a 4 ans
A study to find out if being treated with docetaxel and custirsen (new experimental drug) can increase survival in patients with advanced or metastatic non-small cell lung cancer, compared to the treatment with docetaxel alone. The patients must have received one prior line of platinum-based systemic anticancer therapy
To evaluate if the combination regimen of custirsen and docetaxel improves the Overall Survival (OS) of patients with advanced or metastatic (Stage IV) NSCLC who have received one prior line of platin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
OncoGenex Technologies, Inc
MAJ Il y a 4 ans
The trial is designed to determine the efficacy of OGX-427 Vs placebo in combination with Gemcitabine and Cisplatin in patients with Urinary tract cancer
To ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations